Literature DB >> 18607140

The kidney and hypertension: causes and treatment.

Domenic A Sica1.   

Abstract

Chronic kidney disease is both a cause and a consequence of hypertension. Extracellular volume expansion is an important, if not the most important, contributing factor to hypertension seen in chronic kidney disease. Beyond volume expansion, chronic kidney disease-related hypertension is without truly defining characteristics. Consequently, the sequencing of antihypertensive medications for the patient with chronic kidney disease and hypertension becomes arbitrary. Prescription practice in such patients should be mindful of the need for multiple drug classes with at least one of them being a diuretic. Blood pressure goals in the patient with chronic kidney disease and hypertension are set at lower levels than those for patients with essential hypertension alone. It remains to be determined to what level blood pressure should be lowered in the patient with chronic kidney disease, however.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18607140      PMCID: PMC8110067          DOI: 10.1111/j.1751-7176.2008.08189.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  56 in total

Review 1.  Beta-adrenergic blockers in systemic hypertension: pharmacokinetic considerations related to the current guidelines.

Authors:  William H Frishman; Mamata Alwarshetty
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease.

Authors: 
Journal:  Am J Kidney Dis       Date:  2004-05       Impact factor: 8.860

Review 3.  Antihypertensive therapy in the presence of proteinuria.

Authors:  Pantelis A Sarafidis; Nitin Khosla; George L Bakris
Journal:  Am J Kidney Dis       Date:  2007-01       Impact factor: 8.860

4.  Is neuropeptide Y a contributor to volume-induced hypertension?

Authors:  I Odar-Cederlöf; F Ericsson; E Theodorsson; C M Kjellstrand
Journal:  Am J Kidney Dis       Date:  1998-05       Impact factor: 8.860

Review 5.  Sleeping disorders in patients with end-stage renal disease and chronic kidney disease.

Authors:  Rosa Maria De Santo; Marilŭ Bartiromo; Maria Concetta Cesare; Natale G De Santo; Massimo Cirillo
Journal:  J Ren Nutr       Date:  2006-07       Impact factor: 3.655

6.  Sinus arrest associated with clonidine therapy.

Authors:  E Schwartz; E Friedman; M Mouallem; Z Farfel
Journal:  Clin Cardiol       Date:  1988-01       Impact factor: 2.882

7.  How should patients treated with alpha-blockers be followed? Insights from an ambulatory blood pressure monitoring database.

Authors:  Iddo Z Ben-Dov; Liora Ben-Arie; Judith Mekler; Michael Bursztyn
Journal:  J Hypertens       Date:  2006-05       Impact factor: 4.844

Review 8.  Pathophysiology of hypertensive renal damage: implications for therapy.

Authors:  Anil K Bidani; Karen A Griffin
Journal:  Hypertension       Date:  2004-09-27       Impact factor: 10.190

9.  The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide.

Authors:  H Buter; M H Hemmelder; G Navis; P E de Jong; D de Zeeuw
Journal:  Nephrol Dial Transplant       Date:  1998-07       Impact factor: 5.992

Review 10.  Part 1. Uric acid and losartan.

Authors:  Domenic A Sica; Anton C Schoolwerth
Journal:  Curr Opin Nephrol Hypertens       Date:  2002-09       Impact factor: 2.894

View more
  2 in total

Review 1.  Management of hypertension in chronic kidney disease.

Authors:  Raymond R Townsend; Sandra J Taler
Journal:  Nat Rev Nephrol       Date:  2015-07-28       Impact factor: 28.314

2.  Blood Pressure Changes among Patients Undergoing Hemodialysis in Yenagoa, Nigeria.

Authors:  Oghenekaro Godwin Egbi; Ahmed Sulaiman Daz
Journal:  Niger Med J       Date:  2020-02-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.